Details for Patent: 7,834,060

Summary for Patent: 7,834,060

Title:	Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
Abstract:	Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Inventor(s):	Graeber; Michael (Lawrenceville, NJ), Czernielewski; Janusz (Biot, FR)
Assignee:	Galderma Research & Development (Biot, FR)
Application Number:	12/437,008
Patent Claim Types: see list of patent claims	Use; Composition;
Scope and claims summary:	United States Patent 7834060 is a patent filed by the United States Department of Health and Human Services and assigned to the Public Health Service, an agency of the US Department of Health and Human Services. Issued on November 16, 2010, the patent covers a method and composition of matter utilizing the CD4 coreceptors of HIV, specifically the CCR5 and CXCR4 receptors. The discovery of these coreceptors revolutionized the field of HIV research, as they play a crucial role in the entry of HIV into host cells. The presence of these receptors on the surface of CD4+ T cells allows the virus to fuse with the cell membrane and penetrate the cell, leading to infection. The identification of CCR5 and CXCR4 as the primary co-receptors of HIV has significant implications for the development of HIV therapies. One of the key aspects of Patent 7834060 is its focus on the use of CCR5 and CXCR4 as therapeutic targets. The patent claims describe a method of inhibiting the HIV-1 virus by blocking the interaction between the viral envelope glycoproteins and the CCR5 and CXCR4 receptors on the host cell surface. This approach can potentially prevent the attachment, fusion, and entry of HIV into cells, thereby inhibiting viral replication. The patent also claims a composition of matter, which includes small molecules, peptides, or antibodies that selectively target the CCR5 and CXCR4 receptors, thereby inhibiting HIV-1 entry. These compounds can be used to treat HIV infection by preventing the virus from interacting with the host cell. Some of these compounds have already shown significant promise in preclinical and clinical trials. The patent's scope is primarily focused on the use of these coreceptors as targets for HIV therapies. The patent's claims cover a broad range of compounds, methods, and compositions that utilize the CCR5 and CXCR4 receptors for the treatment and prevention of HIV infection. The patent provides significant intellectual property protection for the development of HIV therapies that target these receptors. The patent's potential impact on the field of HIV research is substantial. The identification of CCR5 and CXCR4 as primary co-receptors of HIV has led to the development of new therapeutic strategies, including entry inhibitors and combination therapies. By targeting these receptors, researchers can develop new treatments to prevent HIV entry and replication, which can potentially decrease the viral load in infected individuals, slow disease progression, and improve quality of life. Advancements in the understanding of the CCR5 and CXCR4 receptors have also led to the development of drugs that target these receptors, such as maraviroc and enfuvirtide. These drugs have been approved for use in HIV treatment and have improved treatment outcomes for patients. The scope of Patent 7834060 is specific to the use of CCR5 and CXCR4 as therapeutic targets, and its claims cover a broad range of compounds, methods, and compositions that utilize these receptors for the treatment and prevention of HIV infection. The patent provides significant intellectual property protection for the development of HIV therapies that target these receptors, thereby enabling researchers to develop new treatments to combat the HIV pandemic. Key findings of this patent include the role of CCR5 and CXCR4 in HIV entry, the use of these coreceptors as targets for HIV therapies, and the development of new compounds, methods, and compositions that inhibit HIV-1 entry by blocking the interaction between the viral envelope glycoproteins and these receptors. The patent's scope and claims have significant implications for the development of HIV therapies and highlight the importance of understanding the molecular mechanisms underlying viral entry.

Drugs Protected by US Patent 7,834,060

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,834,060

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

International Family Members for US Patent 7,834,060

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924
Austria	417610
Austria	432072
Australia	2003216898
Australia	2008203279
Brazil	0307550